1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 27, 1998
-----------------
BIOJECT MEDICAL TECHNOLOGIES INC.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Oregon
----------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-15360 93-1099680
------------------------ --------------------------------
(Commission File Number) (IRS Employer Identification No.)
7620 SW Bridgeport Road
Portland, Oregon 97224
- --------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (503) 639-7221
--------------
N/A
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
2
ITEM 5. OTHER EVENTS
TEXT OF PRESS RELEASE
BIOJECT ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER
Resignation Effective April 30, 1998
_______________________________________________________________________
PORTLAND, OR - March 26, 1998 - Bioject Medical Technologies, Inc.
(NASDAQ: BJCT), the leading manufacturer of jet injection devices for
needle-free subcutaneous and intramuscular injections, today announced
the resignation of Peggy Miller, the company's vice president, chief
financial officer and secretary/treasurer. This resignation will be
effective April 30, 1998.
Said Jim O'Shea, company chairman and chief executive officer, "Peggy
has made significant contributions during the five years she has been
with Bioject, and she has played a critical role in setting the stage
for our further growth. We understand her desire for new challenges
and we wish her well."
O'Shea continued, "We have initiated a search for a new chief financial
officer and hope to make an announcement soon."
Bioject develops, manufactures and markets jet injection systems for
needle-free drug delivery. The Company's advanced injection management
system, the Biojector 2000, has received the Seal of Acceptance from
the Alliance of Children's Hospitals, Inc. and is being marketed to
hospitals, public health clinics, and physician offices. The Company
is also developing a system for Hoffmann-La Roche to market
specifically with their products.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOJECT MEDICAL TECHNOLOGIES INC.
Date: March 27, 1998 By /s/ Peggy J. Miller
----------------------------------
Peggy J. Miller
Vice President, Chief Financial
Officer, Secretary/Treasurer